Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
NCT06226883 is registered in ClinicalTrials.gov with Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 18, 2024
- Completion date
- June 30, 2030
- Enrollment
- 385 (estimated)
- Sites
- 225
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease, inflammatory bowel diseases